Carlsmed, Inc. (NASDAQ:CARL) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Carlsmed, Inc. (NASDAQ:CARL) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $19.25.

A number of research analysts recently commented on the stock. Needham & Company LLC assumed coverage on shares of Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. BTIG Research reissued a “buy” rating and set a $23.00 price objective on shares of Carlsmed in a research note on Wednesday, May 6th. Truist Financial upped their price objective on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th.

Carlsmed Trading Up 6.3%

Shares of CARL opened at $16.50 on Friday. The stock has a market capitalization of $450.45 million and a PE ratio of -11.54. The company’s fifty day moving average is $12.14 and its 200 day moving average is $11.42. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.66 and a current ratio of 8.84. Carlsmed has a fifty-two week low of $8.50 and a fifty-two week high of $17.19.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The business had revenue of $18.94 million during the quarter. Sell-side analysts expect that Carlsmed will post -1.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Carlsmed in the third quarter valued at approximately $33,000. JPMorgan Chase & Co. purchased a new stake in Carlsmed in the third quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Carlsmed during the third quarter valued at approximately $42,000. Rhumbline Advisers purchased a new position in shares of Carlsmed during the 3rd quarter valued at approximately $79,000. Finally, Wells Fargo & Company MN raised its position in shares of Carlsmed by 61.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after acquiring an additional 2,989 shares during the period.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).